Janus Global Life Sciences Fund (JAGLX)

Sector Experts Seeking Growth and Innovation in Health Care

SHARE CLASS

FUND FACTS (JAGLX)

Inception Date12/31/1998
NAV (As of 12/2/16)$45.87
Total Net Assets (As of 10/31/16)$3.40B
Annual Expense Ratio
(As of fiscal year end 9/30/15)
GROSS 0.95%
NET 0.95%

Performance (As of 9/30/16)
1 Year0.04%
3 Year15.31%
5 Year24.18%
10 Year12.92%
Morningstar (As of 10/31/16)
CategoryHealth
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

123 Funds Rated
Equity
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Returns greater than one year are annualized.

Straight Talk

Quarterly Commentary - Q3 2016

EXECUTIVE SUMMARY

Global health care stocks finished the quarter roughly flat, although biotechnology companies rebounded from early-year weakness due, in part, to acquisition activity.

The Fund outperformed its primary benchmark, largely due to its biotech holdings.

We see innovation continuing to drive the sector, and doubt that the winner of November’s elections will command a sufficient mandate to make wholesale changes to the sector.

FUND MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Fund Manager since 2007
Industry since 1996

Ethan Lovell

Ethan Lovell

Fund Manager since 2016
Industry since 1994